We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Global Critical Care Diagnostics Market Driven by Rising Expenditure in ICUs and Emergency Rooms

By LabMedica International staff writers
Posted on 12 Oct 2022

Critical care diagnostics tests have become essential solutions for patients dealing with life-threatening conditions, which especially require sophisticated invasive monitoring devices alongside other monitoring and life support systems. More...

They are cost-effective and easy to use while providing accurate diagnosis and significantly reducing therapeutic turnaround. The global critical care diagnostics market was valued at USD 1.1 billion in 2020 and is projected to register a CAGR of 5.5% from 2021 to 2031 to reach USD 1.7 billion in 2031, driven mainly by the rising adoption of critical care diagnostic tests across operating rooms, emergency rooms, and intensive care units for meeting the needs of critically ill patients who require immediate attention.

These are the latest findings by Fact.MR (Rockville, MD, USA), a market research and consulting agency.

The growing demand for rapid diagnosis and treatment will continue to drive sales of critical care diagnostic products in the market. Similarly, growing awareness of these tests among physicians and patients, as well as their associated advantages, a rapidly growing geriatric population, and increase in the frequency of chronic diseases such as diabetes, heart disease, and cancer will drive the growth of the critical care diagnostics market over the forecast period. Demand is also being driven by the increasing adoption of telehealth services and remote communications. Rising usage of data management and connectivity through interoperability to electronic health records (EHR) will further boost market growth. However, the high cost of molecular diagnostics and lack of skilled professionals are expected to hamper the growth of the global critical care diagnostics market.

Based on test, the hematology tests segment accounts for a share of 40% of the critical care diagnostics market and is projected to grow at a CAGR of 5% through 2032. Based on end users, the emergency room segment is predicted to register the fastest growth over the forecast period due to rising demand for emergency services from patients seeking rapid medical attention. Patients can also receive emergency treatment without prior appointment and obtain basic life support in the event of severe traumatic situations. As the survival rate of critically ill patients in the emergency department is directly related to the advancement of early recognition and treatment of diseases, the demand for critical care diagnostics will grow at a significant pace in this segment.

Geographically, North America will continue to dominate the global critical care diagnostics market and account for around half of its total revenues due to considerable research and development efforts, and increased use of numerous tests by clinicians in the region. Within North America, the U.S. critical care diagnostics market was valued at around USD 290 million in 2020 and it is expected to grow at a steady pace over the next decade. Continuous advancements in diagnostic technologies are expected to create lucrative growth opportunities for the leading players in the critical care diagnostics market during the forecast period.

Related Links:
Fact.MR 


Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
Online QC Software
Acusera 24•7
Immunofluorescence Analyzer
IFA System
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The approach supports myocardial infarction diagnosis in resource-limited settings by reducing delays between clinical suspicion and biochemical confirmation (Image Credit: Adobe Stock)

Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients

Timely confirmation of myocardial infarction often depends on laboratory testing that may not be immediately available at the point of care. This gap between clinical suspicion and definitive evidence... Read more

Molecular Diagnostics

view channel
Image: The platform analyzes cell-free DNA in blood, searching for minute amounts of tumor-derived fragments among background DNA (Image Credit: Adobe Stock)

Blood Test Could Help Fast-Track Lymphoma Diagnosis in Resource-Limited Settings

Lymphoma can be difficult to distinguish from infections and benign conditions, while definitive diagnosis often depends on surgical tissue sampling and specialized pathology that may not be readily available.... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more

Pathology

view channel
Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.